SG Americas Securities’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
SG Americas Securities's BEAM Position: Q1 2026 in Review
SG Americas Securities reduced its Beam Therapeutics (BEAM) stake by 42% in Q1 2026, selling an estimated $1.2M and leaving 60,180 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1549.
SG Americas Securities first reported a position in BEAM in Q2 2020 and has held it in 21 quarters since. The position peaked at $2.87M in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- SG Americas Securities held 60,180 shares of Beam Therapeutics worth $1.43M as of Q1 2026.
- SG Americas Securities sold 43,289 Beam Therapeutics shares in Q1 2026, an estimated $1.2M.
- Beam Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1549 holding.
- SG Americas Securities first reported a position in Beam Therapeutics in Q2 2020 and has held it in 21 quarters since.
- SG Americas Securities's Beam Therapeutics position peaked at $2.87M in Q4 2025.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.